Fig. 5
A Relative cell viability of B16F10 cells after incubation in different preparation groups (TFBF, TPL, TPL@TFB and TPL@TFBF with and without various compounds). B Expression of Nrf2 and GPX4 proteins after different treatments. C Relative GSH levels in B16F10 cells after different preparations. Data are expressed as the mean ± SD (n = 3). ns, not significant, ****P < 0.0001. D Relative cell viability (compared to the group without inhibitor treatment) of B16F10 cells after different treatments in the presence of DEVD. E Expression of GSDME, GSDME-N and cleaved-caspase-3 proteins after different treatments. F LDH release from B16F10 cells after different treatments. Data are expressed as the mean ± SD (n = 3). ns, not significant, **P < 0.01, ****P < 0.0001. G Annexin V/PI double staining analysis of B16F10 cells treated with different preparations. H Annexin V+/PI+ quantification of (G). Data are expressed as the mean ± SD (n = 3). **P < 0.01, ***P < 0.001, ****P < 0.0001. Release of IL-1β (I), ATP (J) and (K) HMGB1 from B16F10 cells after treatment with different preparations. L Expression of the HMGB1 protein in B16F10 cells after different treatments. Data are presented as the mean ± SD (n = 3). ***P < 0.001, ****P < 0.0001. M Flow cytometric results of CRT exposure from B16F10 cells treated with different agents and (N) quantitative average fluorescence intensity. Data are expressed as the mean ± SD (n = 3). *P < 0.05, ***P < 0.001